Business
AZ and Daiichi Sankyo enter collaboration in novel
AZ and Daiichi Sankyo enter collaboration in novel.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 4048U AstraZeneca PLC 29 March 2019 \n\nThis announcement contains inside information\n \nThe securities proposed to be offered pursuant to the equity placing referred to herein will not be and have not been registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.\n \n28 March 2019 23:30 GMT\n \nAstraZeneca and Daiichi Sankyo enter collaboration\nfor novel HER2-targeting antibody-drug conjugate\n \nCompanies to accelerate and expand development of trastuzumab deruxtecan across breast and other cancers, with the potential to redefine standard of care\n \nFunding via an equity placement of approximately $3.5bn\n \nGuidance for 2019 Core Earnings Per Share remains unchanged; growing accretion from 2020 to a significant contribution in 2023\n \nAstraZeneca has entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.\n \nThe collaboration is aligned with AstraZeneca's science-led strategy in Oncology, which is based on four key scientific platforms: tumour drivers & resistance, DNA damage response, Immuno-Oncology and ADCs.\n \nTrastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression. In 2017, trastuzumab deruxtecan was granted Breakthrough Therapy Designation by the US FDA for the treatment of patients with HER2-positive, locally-advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after trastuzumab emtansine.\n \nA first regulatory submission is scheduled for the second half of 2019 for patients in the advanced or refractory breast cancer setting. Additional development for the treatment of breast, non-small cell lung cancer (NSCLC), gastric and colorectal cancers is ongoing.\n \nThe companies will jointly develop and commercialise trastuzumab deruxtecan worldwide, except in Japan where Daiichi Sankyo will maintain ...